Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2019

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

June 2018,

the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2018

07,

“Compensation-Stock Compensation (Topic

718

): Improvements to Nonemployee Share-Based Payment Accounting”

, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic

718

applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The Company adopted the standard on

January 1, 2019.

The adoption of this standard did

not

have a material impact on the Company’s financial statements.

February 2016,

the FASB issued ASU

2016

“

Leases

,” which increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The Company adopted the standard on

January 1, 2019.

The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which

may

result in changes to the classification of an arrangement as a lease. Under the new standard, an arrangement that conveys the right to control the use of an identified asset by obtaining substantially all of its economic benefits and directing how it is used as a lease, whereas the previous definition focuses on the ability to control the use of the asset or to obtain its output. Quantitative and qualitative disclosures related to the amount, timing and judgements of an entity’s accounting for leases and the related cash flows are expanded. Disclosure requirements apply to both lessees and lessors, whereas previous disclosures related only to lessees. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have

not

significantly changed from previous GAAP. Lessor accounting is also largely unchanged.

The new standard provides a number of transition practical expedients, which the Company has elected, including:

	●	A “package of three” expedients that must be taken together and allow entities to ( 1 ) not reassess whether existing contracts contain leases, ( 2 ) carryforward the existing lease classification, and ( 3 ) not reassess initial direct costs associated with existing leases, and
	●	An implementation expedient which allows the requirements of the standard in the period of adoption with no restatement of prior periods.

The impact of adoption did

not

have a material impact to the Company as of

January 1, 2019

as the Company’s finance leases are immaterial and its operating leases had terms shorter than

one

year. In

January 2019,

the Company signed an amendment to its lease for office space at its corporate headquarters in Rancho Cordova, CA. The amendment extended the lease term by

five

years and was accounted for as a modification. At that time, the Company recorded lease assets and liabilities of

$966,000.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Revenue is recognized based on the

five

-step process outlined in Accounting Standards Codification (“ASC”)

606:

The following tables summarize the revenues of the Company’s reportable segments:

	Three Months Ended March 31, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	1,267,000	$	55,000			$	1,322,000
BioArchive		599,000		415,000				1,014,000
CAR-TXpress		307,000		--				307,000
Manual Disposables		294,000		--				294,000
Other		--		--	$	14,000		14,000
Total Device Segment		2,467,000		470,000		14,000		2,951,000
Clinical Development Segment:
Manual Disposables		6,000		--		--		6,000
Other		5,000		--		--		5,000
Total Clinical Development		11,000		--		--		11,000
Total	$	2,478,000	$	470,000	$	14,000	$	2,962,000

	Three Months Ended March 31, 2018
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	685,000	$	65,000			$	750,000
BioArchive		423,000		344,000				767,000
Manual Disposables		233,000		--				233,000
CAR-TXpress		18,000		--				18,000
Other		20,000		--	$	17,000		37,000
Total Device Segment		1,379,000		409,000		17,000		1,805,000
Clinical Development Segment:
Manual Disposables		22,000		--		--		22,000
Bone Marrow		--		23,000		--		23,000
Other		--		17,000		--		17,000
Total Clinical Development		22,000		40,000		--		62,000
Total	$	1,401,000	$	449,000	$	17,000	$	1,867,000

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does

not

have any material contract assets. When invoicing occurs prior to revenue recognition a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the

three

months ended

March 31, 2019

that were included in the beginning balance of deferred revenue were

$383,000.

Short term deferred revenues was

$764,000

and

$485,000

March 31, 2019

and

December 31, 2018,

respectively. Long term deferred revenue, included in other noncurrent liabilities, was

$300,000

and

$303,000

March 31, 2019

and

December 31, 2018,

respectively.

Backlog of Remaining Customer Performance Obligations

The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

	Remainder of 2019		2020		2021		2022		2023 and beyond		Total
Service Revenue	$	1,047,000	$	683,000	$	413,000	$	75,000		--	$	2,218,000
Clinical Revenue		10,000		14,000		14,000		14,000	$	198,000		250,000
Total	$	1,057,000	$	697,000	$	427,000	$	89,000	$	198,000	$	2,468,000

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value

Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs reflecting the reporting entity’s own assumptions.

The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. The impairment of goodwill and intangible assets is a non-recurring Level

fair value measurement.

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets.

The Company has

two

reportable business segments:

	●	The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.
	●	The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have

vesting or other contingencies associated with them. There were

2,465,000

pre-funded warrants included in the quarter ended

March 31, 2019

calculation. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at

March 31:

	2019		2018
Common stock equivalents of convertible promissory note and accrued interest		50,967,211		--
Vested Series A warrants		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529
Warrants – other		15,578,847		4,030,600
Stock options		2,909,338		1,206,410
Restricted stock units		--		416
Total		70,558,337		6,340,367

(

)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the

second

close of the

August 2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February 2021.

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did

not

have an impact on net loss as previously reported.